Clinical Trial Update: Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial reports results on the clinical accuracy of Gallium-68 PSMA PET/CT imaging for detecting biochemical recurrence of prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Gallium-68 PSMA PET radiotracer (68Ga-PSMA)

Snippet

Sponsor: Michael Graham PhD, MD | Conditions: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-04-17